SEC Form 4 · accession 0001209191-19-008521
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Isaac E. Ciechanover
Officer — Chief Executive Officer · Director
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 4:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2019 | F | 24,683 | $0.00 | D | 375,611 | D | |
| Common StockF2 | holding | — | — | — | 329,269 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold to cover tax obligation from settlement of vested restricted stock units.
- F2Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.